Works matching IS 15330028 AND DT 2017 AND VI 16 AND IP 2


Results: 20
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.

    Published in:
    2017
    By:
    • Ann-Lii Cheng;
    • Cornelio, Gerardo;
    • Lin Shen;
    • Price, Timothy;
    • Tsai-Sheng Yang;
    • Ik Joo Chung;
    • Guang-Hai Dai;
    • Jen-Kou Lin;
    • Sharma, Atul;
    • Kun-Huei Yeh;
    • Brigette Ma;
    • Zaatar, Adel;
    • Zhongzhen Guan;
    • Masood, Nehal;
    • Srimuninnimit, Vichien;
    • Thomas Yau;
    • Gibbs, Peter;
    • Xiuwen Wang;
    • Doval, Dinesh Chandra;
    • Seung-Taek Oh
    Publication type:
    journal article
    10
    11
    12
    13
    14

    Ectopic Gastric and Intestinal Phenotypes, Neuroendocrine Cell Differentiation, and SOX2 Expression Correlated With Early Tumor Progression in Colorectal Laterally Spreading Tumors.

    Published in:
    2017
    By:
    • Takahito Katano;
    • Tsutomu Mizoshita;
    • Hironobu Tsukamoto;
    • Hirotada Nishie;
    • Yusuke Inagaki;
    • Noriyuki Hayashi;
    • Satoshi Nomura;
    • Keiji Ozeki;
    • Yasuyuki Okamoto;
    • Takaya Shimura;
    • Yoshinori Mori;
    • Eiji Kubota;
    • Satoshi Tanida;
    • Hiromi Kataoka;
    • Toshiya Kuno;
    • Satoru Takahashi;
    • Takashi Joh;
    • Katano, Takahito;
    • Mizoshita, Tsutomu;
    • Tsukamoto, Hironobu
    Publication type:
    journal article
    15
    16

    Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.

    Published in:
    2017
    By:
    • Takayuki Yoshino;
    • Hiroyuki Uetake;
    • Katsuya Tsuchihara;
    • Kohei Shitara;
    • Kentaro Yamazaki;
    • Eiji Oki;
    • Takeo Sato;
    • Takeshi Naitoh;
    • Yoshito Komatsu;
    • Takeshi Kato;
    • Kazunori Yamanaka;
    • Kouji Iwasaki;
    • Jumpei Soeda;
    • Masamitsu Hihara;
    • Takeharu Yamanaka;
    • Atsushi Ochiai;
    • Kei Muro;
    • Yoshino, Takayuki;
    • Uetake, Hiroyuki;
    • Tsuchihara, Katsuya
    Publication type:
    journal article
    17
    18
    19
    20

    A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).

    Published in:
    2017
    By:
    • Pinter, Tamás;
    • Klippel, Zandra;
    • Cesas, Alvydas;
    • Croitoru, Adina;
    • Decaestecker, Jochen;
    • Gibbs, Peter;
    • Hotko, Yevhen;
    • Jassem, Jacek;
    • Kurteva, Galina;
    • Novotny, Jan;
    • O'Reilly, Seamus;
    • Salek, Tomas;
    • Reiner, Maureen;
    • Morrow, Phuong Khanh;
    • Mi Rim Choi;
    • Whittaker, Sadie;
    • Blanke, Charles;
    • Choi, Mi Rim
    Publication type:
    journal article